Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07164443 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotableLead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLCStudy sites: 173 to 174 · Eligibility criteria shortened, about 7 words · Secondary endpoints: details revised at 5 of 9 entriesShow 3 more changesShow less
Study sites: 173 to 174
Eligibility criteria shortened, about 7 words
Secondary endpoints: details revised at 5 of 9 entries
NotablePrimary completion pushed from Dec 29, 2027 to Aug 18, 2028v14
MinorTrial arms changed: 2 → 5Study sites: 172 to 173 · Interventions: Best Supportive Care (BSC) (Drug), Pasritamig (Biological), Placebo (Other) to Best Supportive Care (BSC) (Drug), JNJ-87189401 (Biological), Pasritamig (Biological), Placebo (Other) · Eligibility criteria shortened, about 22 words · 2 morev13Show 5 more changesShow less
Study sites: 172 to 173
Interventions: Best Supportive Care (BSC) (Drug), Pasritamig (Biological), Placebo (Other) to Best Supportive Care (BSC) (Drug), JNJ-87189401 (Biological), Pasritamig (Biological), Placebo (Other)
Eligibility criteria shortened, about 22 words
Secondary endpoints: details revised at 1 of 9 entries
NotableEnrollment increased: 663 → 1203 participantsCompletion moved earlier from Oct 18, 2028 to Aug 18, 2028 · Site details revised at 2 of 172 sitesv12Show 2 more changesShow less
Completion moved earlier from Oct 18, 2028 to Aug 18, 2028
Site details revised at 2 of 172 sites
MinorTrial sites expanded: 168 → 172 locationsCompletion pushed from Dec 29, 2027 to Oct 18, 2028v11Show 1 more changeShow less
Completion pushed from Dec 29, 2027 to Oct 18, 2028
MinorPrimary and study completion moved earlier from May 30, 2028 to Dec 29, 2027Study sites: 166 to 168v10Show 1 more changeShow less
Study sites: 166 to 168
MinorTrial sites expanded: 163 → 166 locationsv9
MinorStudy sites: 162 to 163v8
MinorStudy sites: 81 to 162Eligibility criteria expanded, about 85 wordsv7Show 1 more changeShow less
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 7 to 12 · Start date changed from estimate of Sep 30, 2025 to Sep 2, 2025 · Eligibility criteria revised · 1 morev2Show 4 more changesShow less
Study sites: 7 to 12
Start date changed from estimate of Sep 30, 2025 to Sep 2, 2025
Eligibility criteria revised
Secondary endpoints: details revised at 9 of 9 entries
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 with JNJ-87189401+BSC as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).